On November 19, 2019, EBT Medical Inc. secured a US$10 million Series A investment, co-led by SV Health Investors and Genesys Capital. EBT intends to use the funding to further develop its noninvasive neuromodulation technology, as well as to pursue additional clinical data validating its safety and effectiveness. Funding will also be used to expand the management team and for general administrative purposes.
EBT Medical Inc. is a clinical-stage startup developing disruptive neuromodulation therapies for pelvic health disorders.
SV Health Investors is a global leader in healthcare and life sciences. SV has been investing in the United States and Europe for more than 25 years and is currently managing $2.2 billion of assets exclusively on healthcare including: healthcare services and IT, biotechnology and medical device.
Osler, Hoskin & Harcourt LLP advised SV Health Investors with a team consisting of Chad Bayne, Gary Marshall and Sahil Chopra (Emerging and High Growth Companies).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Partner, Emerging and High Growth Companies, Toronto
Associate, Emerging and High Growth Companies, Toronto
